In-Vitro & In-Vivo Studies to Support the World’s First CRISPR/RNATargeting Therapy, HG202, for Patients with Neovascular Age-Related Macular Degeneration
Time: 2:00 pm
day: Day Two
Details:
- Highlight the significant unmet medical need for effective treatments for neovascular age-related macular degeneration
- Explain the molecular composition, mechanism of action, and preclinical studies of HG202 using animal models
- Outline the clinical trial design, preliminary safety data, and case studies demonstrating the clinical efficacy of HG202
